Results 31 to 40 of about 2,141 (187)

Combined Abrocitinib and Acitretin Therapy for Darier’s Disease: A Case Report

Clinical, Cosmetic and Investigational Dermatology
Hui Ye,1,2,* Weifeng Chen,1,2,* Wenyan Liu,1,2 Junhui Zhu,1,2 Jingyao Liang,1,2 Xibao Zhang1,2 1Institute of Dermatology, Guangzhou Medical University, Guangzhou, Guangdong, 510095, People’s Republic of China; 2Department of Dermatology ...
Ye H, Chen W, Liu W, Zhu J, Liang J, Zhang X   +5 more
doaj   +1 more source

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice

Dermatology and Therapy, 2023
Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily ...
Melinda J. Gooderham, Andrew E. Pink, Eric L. Simpson, Jonathan I. Silverberg, Erman Güler, Melissa Watkins   +5 more
doaj   +1 more source

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Heliyon, 2023
Background: The sparsity of head-to-head trials for medications used as in atopic dermatitis (AD) treatment makes therapy options difficult. Objective: To better compare the efficacy and safety of abrocitinib and upadacitinib with dupilumab in patients ...
Qin Gao, Yanxia Zhao, Junling Zhang
doaj   +1 more source

Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: A plain language summary

, 2022
Atopic dermatitis (AD, also called atopic eczema) is a long-term skin disease that causes intensely itchy, red skin. Healthcare providers can prescribe medicated creams and ointments to reduce the signs and symptoms of AD.
Valdez, H, DIbonaventura, M, Chu, CY, Malhotra, B, Forman, S, Antinew, J, Ionita, I, Rojo, R, Simpson, EL, Sinclair, R, Kataoka, Y, Zhang, F, Biswas, P, Pink, AE, Zdybski, J, Thaçi, D, Bieber, T, Paul, C, Silverberg, JI   +18 more
core   +2 more sources

Abrocitinib. Tyrosine-protein kinase JAK1 inhibitor, Treatment of atopic dermatitis

, 2021
Atopic dermatitis (AD) is one of the most common chronic skin diseases and has an unmet need for effective therapeutic options. Key components in the pathophysiology of AD rely on the JAK-STAT signaling pathway and JAK inhibition has therefore emerged as
Yao, Y., Zhang, D.G., Ali, Z., Thomsen, S., Zhang, D. G.   +4 more
core   +1 more source

Successful Treatment of Refractory Erythroderma with Abrocitinib: A Case Report. [PDF]

Case Rep Dermatol
INTRODUCTION: Erythroderma represents a severe dermatological condition often challenging to treat, especially in cases unresponsive to standard therapies.
Zhang Y, Li C, Lu C, Yu J.
europepmc   +2 more sources

Abrocitinib/upadacitinib eller dupilumab vid måttlig till svår atopisk dermatit?

, 2022
Bakgrund: Atopisk dermatit (AD) är en vanlig kronisk inflammatorisk hudsjukdom som kännetecknas av eksematösa vätskande sår och intensiv klåda. AD är dels en T-hjälparcell (TH) - 2 driven sjukdom vilket innefattar den akuta fasen av sjukdomen där TH2 ...
Linde, Paulina
core   +3 more sources

Abrocitinib: A panacea for atopic dermatitis

World Journal of Biology Pharmacy and Health Sciences, 2023
Atopic Dermatitis [AD] is a chronic relapsing inflammatory dermatological disease characterized by itch, dry skin, localized or disseminated eczematous lesions and hyperpigmentation of skin. There are several exogeneous and endogenous risk factors for development of AD.
AISWARYA S, ARCHANA SURESH, SIDHARTH PS, BINCY BABU, SHAIJU S DHARAN   +4 more
openaire   +2 more sources

Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life

Journal of Dermatological Treatment, 2022
Background Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials.Methods These analyses included data for Investigator’s ...
Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, Michael C. Cameron   +8 more
doaj   +1 more source

Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)

Medicine in Drug Discovery, 2023
Abrocitinib stands as a targeted therapy, functioning as an inhibitor of Janus kinase (JAK) 1. This pharmaceutical advancement has been meticulously crafted to address the challenges of moderate to severe atopic dermatitis (AD), a prevalent skin ailment ...
Daniela Bermeo Grajales, Nermala Sewdat, Ryan Leo, Supratik Kar   +3 more
doaj   +1 more source